1. Home
  2. CZNC vs CCCC Comparison

CZNC vs CCCC Comparison

Compare CZNC & CCCC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Citizens & Northern Corp

CZNC

Citizens & Northern Corp

HOLD

Current Price

$21.88

Market Cap

377.5M

Sector

Finance

ML Signal

HOLD

Logo C4 Therapeutics Inc.

CCCC

C4 Therapeutics Inc.

HOLD

Current Price

$3.87

Market Cap

404.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CZNC
CCCC
Founded
1864
2015
Country
United States
United States
Employees
N/A
N/A
Industry
Major Banks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
377.5M
404.7M
IPO Year
2009
2020

Fundamental Metrics

Financial Performance
Metric
CZNC
CCCC
Price
$21.88
$3.87
Analyst Decision
Hold
Strong Buy
Analyst Count
1
6
Target Price
$23.50
$12.20
AVG Volume (30 Days)
37.2K
2.9M
Earning Date
05-12-2026
05-06-2026
Dividend Yield
4.87%
N/A
EPS Growth
7.64
16.45
EPS
0.02
N/A
Revenue
N/A
$35,947,000.00
Revenue This Year
$3.11
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$1,096.25
N/A
Revenue Growth
N/A
1.02
52 Week Low
$18.16
$1.36
52 Week High
$24.12
$4.60

Technical Indicators

Market Signals
Indicator
CZNC
CCCC
Relative Strength Index (RSI) 58.38 54.33
Support Level $20.02 $2.13
Resistance Level $22.48 $3.89
Average True Range (ATR) 0.41 0.38
MACD 0.19 -0.05
Stochastic Oscillator 90.00 31.95

Price Performance

Historical Comparison
CZNC
CCCC

About CZNC Citizens & Northern Corp

Citizens & Northern Corp is a community bank operating through its subsidiaries. It provides banking services, including deposit and loan products for personal and commercial customers. The bank also maintains a trust division that provides a wide range of financial services, such as 401(k) plans, retirement planning, estate planning, estate settlements and asset management.

About CCCC C4 Therapeutics Inc.

C4 Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to delivering on the promise of targeted protein degradation science to create a new generation of medicines that transforms patient's lives. The Company is progressing targeted oncology programs through clinical studies and leveraging its TORPEDO platform to efficiently design and optimize small-molecule medicines to address difficult-to-treat diseases. The degrader medicines of the company are designed to harness the body's natural protein recycling system to rapidly degrade disease-causing proteins, offering the potential to overcome drug resistance, and drug undruggable targets and improve patient outcomes. Its pipeline is Cemsidomide, CFT8919, and other discovery products.

Share on Social Networks: